Breaking News Instant updates and real-time market news.

EGY

VAALCO Energy

$2.17

-0.12 (-5.24%)

, MYL

Mylan

$38.48

-0.36 (-0.93%)

18:42
06/04/18
06/04
18:42
06/04/18
18:42

On The Fly: After Hours Movers

HIGHER: VAALCO Energy (EGY), up 8.3% after the company regained NYSE compliance... Mylan (MYL), up 5.2% after the FDA approved Mylan's Fulphila... Twitter (TWTR), up 3.7% after it was named to join the S&P 500. DOWN AFTER EARNINGS: Ascena Retail (ASNA), down 10.9%... Tarena (TEDU), down 4.6%. ALSO LOWER: Deciphera (DCPH), down 6% after it filed to sell 3.75M shares of common stock... Amgen (AMGN), down 1.4% after a Neulasta biosimilar was approved by the FDA.

EGY

VAALCO Energy

$2.17

-0.12 (-5.24%)

MYL

Mylan

$38.48

-0.36 (-0.93%)

TWTR

Twitter

$37.92

1.28 (3.49%)

ASNA

Ascena Retail

$3.65

0.32 (9.61%)

TEDU

Tarena

$9.44

-0.23 (-2.38%)

DCPH

Deciphera

$38.35

12.47 (48.18%)

AMGN

Amgen

$185.48

1.79 (0.97%)

  • 04

    Jun

  • 04

    Jun

  • 05

    Jun

  • 27

    Jul

  • 13

    Nov

  • 07

    Jun

EGY VAALCO Energy
$2.17

-0.12 (-5.24%)

MYL Mylan
$38.48

-0.36 (-0.93%)

05/18/18
BERN
05/18/18
NO CHANGE
Target $54
BERN
Outperform
Biocon 483 letter won't delay approval of Mylan's Neulasta, says Bernstein
Bernstein analyst Aaron Gal said that the 483 letter for Biocon's Bangalore facility contains seven observations, all related to cleaning procedures, and does not contain any argument of systemic or recurring problem, suggestions of any of the procedure deviations creating patient risk or problems requiring changes in the facility structure or equipment. In a research note to investors, Gal said the 483 is viewed as being on the "lighter side," and can be "reasonably" addressed through change in procedure, and does not believe it will delay the tentative approval of Biocon/Mylan's Neulasta. The analyst has an Outperform rating and $54 price target on Mylan.
05/15/18
MZHO
05/15/18
UPGRADE
Target $27
MZHO
Buy
Mizuho compares Valeant portfolio to Mylan in upgrade to Buy
Mizuho analyst Irina Koffler upgraded Valeant Pharmaceuticals (VRX) to Buy from Neutral and raised her price target for the shares to $27 from $15. The stock closed yesterday down 4c to $20.81. Adjusting individual product growth estimates has made the analyst more constructive on Valeant's turnaround story. The company's portfolio now looks Mylan-like (MYL) in that 70% of revenue consists of stable products that are either consumer-focused, or older drugs that are already generic, Koffler tells investors in a research note. Further, the analyst sees growth potential from Valeant's pipeline, which she notes contains multiple catalysts in 2018-2020 and is not in her estimates. She thinks that in order for the stock to work over the next year, Valeant just needs to execute on its quarters and push through new product launches.
05/23/18
JPMS
05/23/18
NO CHANGE
Target $53
JPMS
Overweight
Mylan risk/reward favorable into June catalysts, says JPMorgan
JPMorgan analyst Chris Schott sees a favorable setup and risk/reward for Mylan shares heading into June. His downside case, in which biosimilar Neulasta, generic Advair and generic Restasis do not get approved in 2018, supports earnings per share in the low $5 range and a stock that he struggles to see sustainably below the mid $30's. The analyst's upside case, which has some mix of Advair, Neulasta and Restasis approved, supports a share price "well above" $50. Looking beyond near-term catalysts, Schott believes Mylan is "very well-positioned" within the generics space. He keeps an Overweight rating on the shares with a $53 price target.
04/25/18
WELS
04/25/18
NO CHANGE
WELS
Market Perform
Glaxo comments on Advair have negative read through for Mylan, says Wells Fargo
Noting that GlaxoSmithKline (GSK) said it now expects branded Advair sales to decline 30% this year, even excluding the impact of a generic, Wells Fargo analyst David Maris said the news has a negative read through for Mylan (MYL) given that its generic Advair is one of the company's highest profile pipeline items. While Advair will be a good generic opportunity, it represents "a fraction of what some might have previously believed," said Maris, who has a Market Perform rating on Mylan shares.
TWTR Twitter
$37.92

1.28 (3.49%)

05/02/18
DBAB
05/02/18
NO CHANGE
Target $32
DBAB
Buy
Twitter price target raised to $32 from $22 at Deutsche Bank
Deutsche Bank analyst Lloyd Walmsley raised his price target for Twitter to $32 while keeping a Hold rating on the shares. The analyst feels "increasingly positive" on Twitter due to "strong" product and business momentum across user engagement and monetization. However, he remains on the sidelines given the stock's "premium valuation on relatively slower growth."
06/01/18
MKMP
06/01/18
NO CHANGE
Target $43
MKMP
Buy
World Cup may be more meaningful driver for Twitter vs. 2014, says MKM Partners
MKM Partners analyst Rob Sanderson raised his price target on Twitter to $43 from $40 and maintained a Buy rating, telling investors in a research note that the impact of the World Cup could be a more meaningful driver for Twitter than in 2014, as the service is much improved since then and video was nascent on Twitter in 2014 but is now the largest source of monetization. He thinks the potential for Twitter to become a mass-market service in the future "still exists," which could lead to a significant revaluation if it happens.
04/30/18
BARD
04/30/18
NO CHANGE
Target $33
BARD
Neutral
Twitter's new partnerships highlight 'growing relevance,' says Baird
Disney's (DIS) and Viacom's (VIAB) announced live content/streaming partnerships with Twitter (TWTR) highlight Twitter's "growing relevance as a distribution platform," Baird analyst Colin Sebastian tells investors in a research note. He believes the partnerships should provide tailwinds for Twitter's video advertising business. Video accounts for greater than 50% of Twitter ad revenue and is its fastest growing ad format, Sebastian points out. The analyst says Disney and Viacom represent two of the company's biggest partnership wins to-date. He keeps a Neutral rating on Twitter with a $30 price target. The stock closed the trading day up 4.5% to $30.31.
05/02/18
JEFF
05/02/18
NO CHANGE
Target $14
JEFF
Hold
Snap price target lowered to $14 from $17 at Jefferies
Snap last night posted the lowest top line growth it has seen as a public company and user metrics "show more trouble ahead," Jefferies analyst Brent Thill tells investors in a post-earnings research note titled "Ongoing Growing Pains." The analyst continues to recommend Facebook (FB) in Social and is more positive on Twitter (TWTR) than Snap during the latter's redesign. He lowered his price target for Snap to $14 and keeps a Hold rating on the shares.
ASNA Ascena Retail
$3.65

0.32 (9.61%)

08/15/17
08/15/17
NO CHANGE

FBR lowers Specialty Retail price targets ahead of Q2 reports
FBR Capital analyst Susan Anderson expects Specialty Retail earnings in Q2 to be overall in-line with consensus estimates, with a lighter top line and gross margin given the need to promote to drive traffic. The analyst views American Eagle (AEO) and L Brands (LB) as winners in the quarter. She upgraded American Eagle this morning to Buy. Anderson also lowered her price target for Neutral-rated Abercrombie & Fitch (ANF) to $11 from $13, for Neutral-rated Ascena Retail (ASNA) to $3 from $5, for Neutral-rated Foot Locker (FL) to $58 from $66, for Neutral-rated Francesca's to $10 from $13, for Neutral-rated Gap (GPS) to $25 from $28 and for Neutral-rated Urban Outfitters (URBN) to $16 from $24.
TEDU Tarena
$9.44

-0.23 (-2.38%)

08/22/17
NOMU
08/22/17
DOWNGRADE
Target $19.5
NOMU
Neutral
Tarena downgraded to Neutral from Buy at Nomura Instinet
Nomura Instinet analyst Andrew Orchard downgraded Tarena to Neutral and lowered its price target to $19.50 from $20.50 following weak Q3 revenue and margin guidance. The analyst expects margin softness to persist due to slower revenue recognition, higher R&D, and sustained investments and said underlying demand for certain classes may be weak as well.
11/22/17
JEFF
11/22/17
DOWNGRADE
Target $14.75
JEFF
Hold
Tarena downgraded to Hold from Buy at Jefferies
Jefferies analyst Johnny Kin Man Wong downgraded Tarena International to Hold and cut his price target for the shares to $14.75 from $21.50. The company's "aggressive" learning center rollout will be a drag on margins and "should cause some short term pain," Wong tells investors in a research note. The analyst, however, is positive on Tarena expanding into the K12 business.
04/04/18
LYON
04/04/18
UPGRADE
LYON
Buy
Tarena upgraded to Buy from Outperform at CLSA
DCPH Deciphera
$38.35

12.47 (48.18%)

06/03/18
PIPR
06/03/18
NO CHANGE
Target $35
PIPR
Overweight
Piper Jaffray incrementally positive on Deciphera shares
Piper Jaffray analyst Christopher Raymond is ncrementally positive on Deciphera's (DCPH) shares after what he sees as meaningfully de-risking data for DCC-2618 in refractory GIST at ASCO over the weekend. The analyst sees two key takeaways from the data, namely that DCC-2618 continues to compare well to Blueprint Medicines' (BPMC) BLU-285 efficacy wise, while maintaining a more favorable safety profile, and as he thinks Deciphera's 2L registration trial is meaningfully de-risked, in that sunitinib consistently confers just a single digit ORR. Raymond reiterates an Overweight rating and $35 price target on Deciphera shares.
05/31/18
PIPR
05/31/18
NO CHANGE
Target $35
PIPR
Overweight
Deciphera shares can outperform biotech index, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond says recent meetings with Deciphera Pharmaceuticals management confirmed his bullish thesis on the name. The shares can outperform the biotech index as key updates on lead drug DCC-2618 in refractory gastrointestinal stromal tumors continue to roll out, starting this weekend at ASCO, Raymond tells investors in a research note. Further, he believes value from the company's systemic mastocytosis opportunity could start to "work its way into the stock" as a key initial read-out nears toward the end of 2018. The analyst keeps an Overweight rating on Deciphera with a $35 price target.
02/15/18
RILY
02/15/18
INITIATION
Target $43
RILY
Buy
Deciphera initiated with a Buy at B. Riley FBR
B. Riley FBR initiated Deciphera with a Buy and $43 price target.
06/04/18
JPMS
06/04/18
NO CHANGE
Target $33
JPMS
Overweight
Deciphera price target raised to $33 from $30 at JPMorgan
JPMorgan analyst Jessica Fye raised her price target for Deciphera to $33 citing the "better-than-expected" phase I update for DCC-2618 at ASCO. The upadted increased the analyst's probability of success in the pivotal 2L Gist trial set to start this year. She keeps an Overweight rating on the shares.
AMGN Amgen
$185.48

1.79 (0.97%)

05/18/18
JEFF
05/18/18
NO CHANGE
Target $200
JEFF
Buy
Amgen price for Aimovig lower than expected, says Jefferies
Jefferies analyst Michael Yee says the confirmed list price of $6,900 for Amgen's (AMGN) Aimovig is lower than Street expectations of $7,000-$10,000. The analyst thinks the net price could fall to around $5,000-$6,000 as Allergan's (AGN) Botox is around $6,000. Amgen's pricing strategy sends a good message and fits well into the current reimbursement environment, Yee tells investors in a research note. He keeps a Buy rating on the shares with a $200 price target.
05/18/18
CANT
05/18/18
NO CHANGE
Target $18
CANT
Neutral
Amgen approval in migraine positive for Teva, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen thinks FDA approval of Amgen's (AMGN) Aimovig is positive for Teva (TEVA) as well as other new potential migraine treatments coming to the market because it underscores the large unmet need. She notes, however, that Teva does not expect approval until later this year given its manufacturing issues. The analyst keeps a Neutral rating on Teva with an $18 price target.
05/18/18
WELS
05/18/18
NO CHANGE
WELS
Amgen migraine drug price may be below expectations, says Wells Fargo
The FDA, as expected, approved Amgen (AMGN) and Novartis' (NVS) first-in-class anti-CGRP treatment Aimovig for the prevention of migraine, Wells Fargo analyst David Maris tells investors in a research note. The only part of the news which may be somewhat unexpected could be the pricing, which came in at $575 per month or $6,900 annually, the analyst adds. He thinks some investors may have been expecting the price in the $12,000 range. Maris thinks there may be a potential negative read-through on the pricing for Teva (TEVA) and to a lesser extent, Allergan (AGN).
05/17/18
PIPR
05/17/18
NO CHANGE
Target $190
PIPR
Overweight
Amgen's Aimovig launch in migraine should beat expectations, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond kept his Overweight rating and $190 price target on Amgen (AMGN) after today's FDA approval of Aimovig in migraine. The analyst notes that this marks the first anti-CGRP therapy approval in what is expected to be a crowded space, adding that Amgen and its partner Novartis (NVS) have "effectively capitalized on their first-mover advantage." The analyst says the smart pricing for the product should allow this launch to "beat expectations".

TODAY'S FREE FLY STORIES

NTGN

Neon Therapeutics

$8.88

0.56 (6.73%)

14:30
10/21/18
10/21
14:30
10/21/18
14:30
Conference/Events
Neon Therapeutics management to meet with Morgan Stanley »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 25

    Oct

  • 26

    Oct

  • 07

    Nov

GTHX

G1 Therapeutics

$46.88

-0.07 (-0.15%)

14:13
10/21/18
10/21
14:13
10/21/18
14:13
Hot Stocks
G1 presents additional data from randomized Phase 2 trial in first-line SCLC »

G1 Therapeutics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

NCNA

NuCana

$18.90

1.9 (11.18%)

14:09
10/21/18
10/21
14:09
10/21/18
14:09
Hot Stocks
NuCana reports additional data on NUC-1031 in advanced biliary tract cancer »

NuCana announced combined…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

LPTX

Leap Therapeutics

$6.44

-0.17 (-2.57%)

, MRK

Merck

$72.34

0.12 (0.17%)

14:05
10/21/18
10/21
14:05
10/21/18
14:05
Hot Stocks
Leap Therapeutics presents esophagogastric cancer data »

Leap Therapeutics (LPTX)…

LPTX

Leap Therapeutics

$6.44

-0.17 (-2.57%)

MRK

Merck

$72.34

0.12 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

INCY

Incyte

$66.09

1.66 (2.58%)

14:02
10/21/18
10/21
14:02
10/21/18
14:02
Hot Stocks
Incyte announces positive interim data from Phase 2 trial of Pemigatinib »

Incyte announced updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 30

    Oct

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

, BAYRY

Bayer

$0.00

(0.00%)

13:58
10/21/18
10/21
13:58
10/21/18
13:58
Hot Stocks
Loxo's larotrectinib delivers 81% ORR in expanded dataset of 109 TRK fusion cancer »

Bayer (BAYRY) and Loxo…

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

BAYRY

Bayer

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 23

    Oct

  • 29

    Oct

  • 26

    Nov

  • 27

    Nov

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

, BAYRY

Bayer

$0.00

(0.00%)

13:53
10/21/18
10/21
13:53
10/21/18
13:53
Hot Stocks
Loxo announces larotrectinib clinical update in patients with TRK fusion cancers »

Loxo Oncology (LOXO)…

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

BAYRY

Bayer

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 23

    Oct

  • 29

    Oct

  • 26

    Nov

  • 27

    Nov

MRTX

Mirati Therapeutics

$40.04

-1.82 (-4.35%)

13:45
10/21/18
10/21
13:45
10/21/18
13:45
Hot Stocks
Mirati announces updated data from ongoing trial of single agent sitravatinib »

Mirati Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

RHHBY

Roche

$0.00

(0.00%)

13:39
10/21/18
10/21
13:39
10/21/18
13:39
Hot Stocks
Entrectinib shrank tumors in people with NTRK fusion-positive solid tumors »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 07

    Nov

  • 24

    Dec

GILD

Gilead

$73.27

-0.9 (-1.21%)

, GLPG

Galapagos NV

$107.66

2.29 (2.17%)

13:34
10/21/18
10/21
13:34
10/21/18
13:34
Hot Stocks
Gilead, Galapagos NV announced data from Phase 3 FINCH2 trial of filgotinib »

Gilead Sciences (GILD)…

GILD

Gilead

$73.27

-0.9 (-1.21%)

GLPG

Galapagos NV

$107.66

2.29 (2.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 07

    Nov

BLRX

BioLineRx

$0.98

-0.22 (-18.33%)

, MRK

Merck

$72.34

0.12 (0.17%)

13:27
10/21/18
10/21
13:27
10/21/18
13:27
Hot Stocks
BioLineRx discloses additional data from Phase 2a COMBAT/KEYNOTE-202 study »

BioLineRx (BLRX)…

BLRX

BioLineRx

$0.98

-0.22 (-18.33%)

MRK

Merck

$72.34

0.12 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

ADAP

Adaptimmune

$10.79

-0.09 (-0.83%)

13:22
10/21/18
10/21
13:22
10/21/18
13:22
Hot Stocks
Adaptimmune presents updated data from ongoing MAGE-A10, MAGE-A4 studies »

Adaptimmune Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

13:02
10/21/18
10/21
13:02
10/21/18
13:02
Hot Stocks
Genentech's Tecentriq, Abraxane combo demonstrates positive Phase III results »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 07

    Nov

  • 24

    Dec

PFE

Pfizer

$44.50

0.48 (1.09%)

12:56
10/21/18
10/21
12:56
10/21/18
12:56
Hot Stocks
Pfizer presents overall survival data from PALOMA-3 trial of Ibrance »

Pfizer announced detailed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 30

    Oct

  • 07

    Nov

MRK

Merck

$72.34

0.12 (0.17%)

12:52
10/21/18
10/21
12:52
10/21/18
12:52
Hot Stocks
Merck presents early data for STING agonist in advanced solid tumors/lymphomas »

Merck announced the first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

DVAX

Dynavax

$10.90

-0.47 (-4.13%)

, MRK

Merck

$72.34

0.12 (0.17%)

12:47
10/21/18
10/21
12:47
10/21/18
12:47
Hot Stocks
Dynavax's SD-101, Keytruda combo still shows 70% ORR in Advanced Melanoma »

Dynavax (DVAX) presented…

DVAX

Dynavax

$10.90

-0.47 (-4.13%)

MRK

Merck

$72.34

0.12 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

EXEL

Exelixis

$16.27

-0.25 (-1.51%)

12:44
10/21/18
10/21
12:44
10/21/18
12:44
Hot Stocks
Exelixis announces results from data analysis of CABOSUN, METEOR trials »

Exelixis announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 01

    Nov

  • 07

    Nov

  • 27

    Nov

  • 14

    Jan

AGEN

Agenus

$1.97

-0.025 (-1.26%)

12:39
10/21/18
10/21
12:39
10/21/18
12:39
Hot Stocks
Agenus presents clinical data on PD-1, CTLA-4 at ESMO 2018 »

Agenus presented updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

OMED

OncoMed

$2.47

-0.17 (-6.44%)

12:37
10/21/18
10/21
12:37
10/21/18
12:37
Hot Stocks
OncoMed announces interim phase 1b results for Navicixizumab, Paclitaxel combo »

OncoMed Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMGN

ImmunoGen

$7.44

-0.355 (-4.56%)

, MRK

Merck

$72.34

0.12 (0.17%)

12:34
10/21/18
10/21
12:34
10/21/18
12:34
Hot Stocks
ImmunoGen presents initial data from FORWARD II expansion cohort »

ImmunoGen (IMGN)…

IMGN

ImmunoGen

$7.44

-0.355 (-4.56%)

MRK

Merck

$72.34

0.12 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 02

    Nov

  • 11

    Jan

  • 16

    Feb

BMY

Bristol-Myers

$54.31

-1.7 (-3.04%)

12:30
10/21/18
10/21
12:30
10/21/18
12:30
Hot Stocks
Opdivo, Yervoy combo shows promising results in advanced form of bladder cancer »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 25

    Oct

  • 29

    Oct

  • 07

    Nov

MRK

Merck

$72.34

0.12 (0.17%)

12:26
10/21/18
10/21
12:26
10/21/18
12:26
Hot Stocks
Merck's Keytruda shows complete response rate of nearly 40% in high-risk NMIBC »

Merck announced the first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

TSRO

Tesaro

$41.81

-1.19 (-2.77%)

12:18
10/21/18
10/21
12:18
10/21/18
12:18
Hot Stocks
Tesaro presents Phase 1 GARNET data of TSR-042 in MSI-H endometrial cancer »

Tesaro summarized updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 07

    Nov

UDR

UDR, Inc.

09:37
10/21/18
10/21
09:37
10/21/18
09:37
Downgrade
UDR, Inc. rating change at Evercore ISI »

UDR, Inc. downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 07

    Nov

AVB

AvalonBay

$178.01

1.725 (0.98%)

09:37
10/21/18
10/21
09:37
10/21/18
09:37
Downgrade
AvalonBay rating change  »

AvalonBay downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.